Academic Title
Associate Professor, Vice Chairman, Director of Reconstructive Urology
Bio Statement
Dr. Sean Elliott is associate professor of urology and director of Reconstructive Urology at the University of Minnesota. He a fellowship-trained reconstructive urologist. His career is focused on improving patients' quality of life by rebuilding injured organs in the genitourinary system. His clinical practice includes reconstruction of urethral strictures, the injured ureter, urinary fistulas, male urinary incontinence, neurogenic bladder, erectile dysfunction, Peyronie's disease and trapped or buried penis.
Elliott has performed more than 200 urethroplasties for urethral stricture disease and is one of the busiest implanters of devices to correct male incontinence in the U.S. He also manages challenging adverse effects of pelvic radiation including radiation cystitis, ureteral and urethral strictures.
Elliott’s research activities complement his clinical activities in that he is working to improve cancer survivorship by addressing the adverse effects of surgery and radiation to the urinary tract. He has completed a Master’s of Science in Health Services Research with a focus on Outcomes Research. He currently holds three nationally competitive research grants and is a member of the Board of Directors of the Society of Genitourinary Reconstructive Surgeons. Elliot also is a participant in the University of Minnesota Medical School’s Emerging Physician Leadership Program.
Research Articles
Loading...
Publications
IMRT and Clinical Characteristics
The Journal of Urology - "Bias Due to Missing SEER Data in D'Amico Risk Stratification of Prostate Cancer"
Elliott SP, Jarosek SA, Wilt TJ and Virnig BA. Reduction in physician reimbursement and hormone therapy use in prostate cancer. JNCI 2010; 102(24):1826-34.
Elliott SP and Malaeb BS. Long-term urinary adverse effects of pelvic radiotherapy. WORLD J UROL 2011; 29(1):35-41.
Malaeb BS, Elliott SP, Lee J, Anderson DW, Timm GW. Novel Artificial Urinary Sphincter in the Canine Model: The Tape Mechanical Occlusive Device. UROLOGY 2011; 77(1):211-6.
Anger JT, Buckley JC, Santucci RA, Elliott SP, Saigal CS; Urologic Diseases in America Project.Trends in Stricture Management Among Male Medicare Beneficiaries: Underuse of Urethroplasty? Urology 2011; 77: 481-6.
Strope SA, Elliott SP, Smith A, Wei JT, Wilt TJ, Saigal CS; Urologic Diseases in America Project. Urologist Practice Styles in the Initial Evaluation of Elderly Men With Benign Prostatic Hyperplasia. Urology 2011; 77(3):535-40.
Elliott SP, Jarosek SL, Alanee SR, Konety BR, Dusenbery KE and Virnig BA. 3-Dimensional External Beam Radiotherapy for Prostate Cancer Increases the Risk of Hip Fracture. Cancer 2011; Epub ahead of print; Mar 16. doi: 10.1002/cncr.25994.
Elliott SP, Wilt TJ and Kuntz KM. Projecting the Clinical Benefits of Adjuvant Radiotherapy versus Observation and Selective Salvage Radiotherapy after Radical Prostatectomy:
A Decision Analysis. Prostate Cancer and Prostatic Disease 2011; in press.
Elliott SP. The evolution of urethral reconstruction. J UROL 2011;185:1564-5.
Strope SA, Elliott SP, Saigal CS, Smith A, Wilt TJ, Wei JT. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. UROLOGY 2011;78:3-9.
Elliott SP, Jarosek SL, and Virnig BA. Changes Across Time and Geography in the Use of Prostate Radiation Technologies for Newly Diagnosed Older Cancer Patients. Types of Prostate Radiation. Data Points #16 (prepared by the University of Minnesota DEcIDE Center, under Contract No.HHSA29020100013I ). Rockville, MD: Agency for Healthcare Research and Quality. September 2011. AHRQ Publication No. 12-EHC095-EF. PMID: 23285489.
Jarosek SL, Elliott SP, Virnig BA. Proton Beam Radiotherapy in the U.S. Medicare Population: Growth in use between 2006 and 2009. Proton Beam Radiotherapy. Data Points #10 (prepared by the University of Minnesota DEcIDE Center, under Contract No. HHSA29020100013I ). Rockville, MD: Agency for Healthcare Research and Quality. September 2011. AHRQ Publication No. 12-EHC005.
Elliott SP, Adejoro OO, Konety BR, Jarosek SL, Dusenbery KE, Virnig BA. Intensity modulated radiation therapy replaces 3-dimensional conformal radiotherapy as prostate cancer treatment. J UROL 2012 Apr;187(4):1253-8. Epub 2012 Feb 14. PMID: 22335868 [PubMed - in process].
Bellinger AS, Elliott SP, Yang L, Wei JT, Saigal CS, Smith A, Wilt TJ, Strope SA. Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. Urologic Diseases in America Project. J UROL 2012 May;187(5):1739-46. Epub 2012 Mar 15. PMID: 22425128 [PubMed - in process].
Elliott SP, Johnson DP, Jarosek SL, Konety BR, Adejoro OO, Virnig BA. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer. J UROL 2012 July;187(6):2026-31. Epub 2012 Apr 11. PMID: 22498210 [PubMed - in process].
Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). UROLOGY 2012 May;79(5):1111-6. PMID: 22546389 [PubMed - indexed for MEDLINE].
Strope SA, Wei JT, Smith A, Wilt TJ, Saigal CS, Elliott SP. Evaluative Care Guideline Compliance Is Associated With Provision of Benign Prostatic Hyperplasia Surgery. The Urologic Diseases in America Project. UROLOGY 2012 Jul;80(1):84-89. Epub 2012 May 18. PMID: 22608799 [PubMed - as supplied by publisher].
Erickson BA, Voelzke BB, Myers JB, Brant WO, Broghammer JA, Smith TG 3rd, McClung CD, Alsikafi NF, Elliott SP. Practice Patterns of Recently Fellowship-trained Reconstructive Urologists. UROLOGY 2012 Oct;80(4):934-7. PMID: 22901817.
Hoffman RM, Monga M, Elliott SP, MacDonald R, Langsjoen J, Tacklind J, Wilt TJ. Microwave thermotherapy for benign prostatic hyperplasia. COCHRANE DATABASE SYST REV. 2012 Sep 12;9:CD004135. PMID: 22972068.
Weight CJ and Elliott SP. The impotent certificate of need. J UROL 2013 Jan;189(1):12-3. PMID: 23089467.
O’Shaughnessy M, Elliott SP, Konety BR, Jarosek SL. Factors associated with reduction in use of neoadjuvant androgen suppression therapy prior to radical prostatectomy. UROLOGY 2012 [in press].
Sewell J, Rao A, Elliott SP. Validating a Claims-Based Method for Assessing Severe Rectal and Urinary Adverse Effects of Radiotherapy. UROLOGY 2013 [in press].
Current Projects
Understanding the severe urinary adverse effects of pelvic radiotherapy
Validating a Claims-Based Method for Assessing Severe Rectal and Urinary Adverse Effects of Radiotherapy
Grants
1) Research Scholar Grant, RSG-12-217-01–CPHPS
American Cancer Society
“Understanding the severe urinary adverse effects of pelvic radiotherapy”
This grant uses the SEER-Medicare database to better understand the severe urinary adverse effects of pelvic radiation such as urethral stricture, urinary fistula and hemorrhagic cystitis. We will describe their long-term incidence, compare risk factors and illustrate the burden of treatment for these events.
2) Medical Education and Research Association Grant
Gillette Children’s Specialty Healthcare
“Gentamycin bladder instillation”
This grant funds a randomized, placebo-controlled trial of nightly gentamycin bladder instillation for the prevention of urinary tract infection in adult Myelomeningocele patients with bladder augmentation.
